GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Price-to-Owner-Earnings

NextCell Pharma AB (OSTO:NXTCL) Price-to-Owner-Earnings : (As of May. 30, 2025)


View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Price-to-Owner-Earnings?

As of today (2025-05-30), NextCell Pharma AB's share price is kr1.08. NextCell Pharma AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NextCell Pharma AB's Price-to-Owner-Earnings or its related term are showing as below:


OSTO:NXTCL's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.765
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-30), NextCell Pharma AB's share price is kr1.08. NextCell Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2025 was kr-0.66. Therefore, NextCell Pharma AB's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-30), NextCell Pharma AB's share price is kr1.08. NextCell Pharma AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr-0.66. Therefore, NextCell Pharma AB's PE Ratio without NRI for today is At Loss.


NextCell Pharma AB Price-to-Owner-Earnings Historical Data

The historical data trend for NextCell Pharma AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Price-to-Owner-Earnings Chart

NextCell Pharma AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NextCell Pharma AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NextCell Pharma AB's Price-to-Owner-Earnings

For the Biotechnology subindustry, NextCell Pharma AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCell Pharma AB's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Price-to-Owner-Earnings falls into.


;
;

NextCell Pharma AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NextCell Pharma AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.08/-0.48
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCell Pharma AB  (OSTO:NXTCL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NextCell Pharma AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCell Pharma AB Business Description

Traded in Other Exchanges
N/A
Address
Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines